A new treatment option for menopausal hot flushes and night sweats can be used in the NHS when hormone replacement therapy (HRT) is not suitable. Fezolinetant (also called Veoza and made by Astellas ...

Nirmatrelvir plus ritonavir and tocilizumab for treating COVID-19 TA878 29 March 2023 26 February 2026 ...

Nirmatrelvir plus ritonavir and tocilizumab for treating COVID-19 TA878 29 March 2023 26 February 2026 ...

Learn how NICE's healthtech guidance helped bring life-changing genetic testing to neonatal units across the UK, saving 20 ...

Suggested remit: To appraise the clinical and cost effectiveness of nusinersen and risdiplam within their marketing authorisations for treating spinal muscular atrophy. Anticipate the topic will be of ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

This guidance has been updated and replaced by dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia ...

Be aware that lower urinary tract infection (UTI) is an infection of the bladder usually caused by bacteria from the gastrointestinal tract entering the urethra and travelling up to the bladder.

A new treatment option for menopausal hot flushes and night sweats can be used in the NHS when hormone replacement therapy (HRT) is not suitable. Ahead of Rare Disease Day on 28 February, we've ...

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy Technology appraisal guidance TA673 Published: 17 ...

Suggested remit: To appraise the clinical and cost effectiveness of belantamab mafodotin within its marketing authorisation for treating relapsed or refractory multiple myeloma after 4 or more ...

This guideline has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) [NG245] ...